Ultrathin StrutBioresorbable polymer stents sets new standard in drug-eluting stent technology

CPD QUESTIONNAIRE

EARN FREE CPD POINTS

Complete, scan and email to **cpd@denovomedica.com**. Alternatively, you can complete this questionnaire online at **www.denovomedica.com**. Fill in your details using **clear block letters** and mark the answers with a tick (✓).

I agree that my CPD-accredited certificate will be forwarded to my e-mail address. (Online) _____

(Signature of healthcare professional)

First Name		**Profession**	
Surname		**Telephone**	
HPC No.		**City**	
E-mail		**Sales Rep.**	

1. The BIOFLOW V clinical trial included patients with:

- ☐ **A** <3 *de novo* coronary artery lesions
- ☐ **B** <2 *de novo* coronary artery lesions

2. Patients were eligible for the trial if:

- ☐ **A** They were undergoing urgent percutaneous coronary intervention
- ☐ **B** They had acute coronary syndromes needing percutaneous coronary intervention
- ☐ **C** They were non-STEMI haemodynamically stable patients requiring percutaneous coronary intervention
- ☐ **D** All of the above

3. The thickness of the ultrathin strut used in the BIOFLOW trial for <3mm diameter struts is:

- ☐ **A** 40µm
- ☐ **B** 60µm
- ☐ **C** 80µm

4. Patients entered into the trial were graded for angiographic complexity; what percentage of patients had moderate/severe vessel tortuosity?

- ☐ **A** >60%
- ☐ **B** >70%
- ☐ **C** >80%

5. The Orsiro stent elutes what percentage of the sirolimus (1.4µg/mm²) in the first 90 days?

- ☐ **A** 60%
- ☐ **B** 70%
- ☐ **C** >80%

6. TLF in patients who received the BP-SES was what percentage lower than in those who received the comparator DP-EES?

- ☐ **A** 20%
- ☐ **B** 40%
- ☐ **C** 30%

7. What percentage of patients experienced target vessel-related MI in the BP-SES arm over the three-year period?

- ☐ **A** 6.9%
- ☐ **B** 9.5%
- ☐ **C** 5.5%

8. Target lesion revascularisation caused by ischaemia was how much lower in the bioresorbable stent arm?

- ☐ **A** >50%
- ☐ **B** 40%
- ☐ **C** >40%

9. Stent thrombosis, either definite/probable, was how much lower using the ultrathin bioresorbable stent than the DP-EES?

- ☐ **A** 90%
- ☐ **B** 70%
- ☐ **C** 50%

10. In a meta-analysis of eight RCTs (>10 000 patients), when using an ultrathin bioresorbable stent, TLF was on average how much lower than with a second-generation DP-EES?

- ☐ **A** 5%
- ☐ **B** 10%
- ☐ **C** 15%

© 2020 deNovo Medica